Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | AOC2 | O75106 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678060 | 0.82 | ITGB2 (0.39) | NISCHTP53SIGMAR1HTR1A | |
| SCHEMBL31258280 | 0.76 | ROCK2 (0.39) | — | |
| SCHEMBL31258118 | 0.76 | ROCK2 (0.39) | MAOB | |
| SCHEMBL6377640 | 0.76 | ROCK2 (0.39) | MAOB | |
| SCHEMBL31257959 | 0.76 | ROCK2 (0.39) | — | |
| SCHEMBL24131486 | 0.76 | ROCK2 (0.39) | — | |
| SCHEMBL385636 | 0.75 | IDO1 (0.41) | MAOA | |
| SCHEMBL28869631 | 0.74 | SIGMAR1 (0.46) | NISCHTP53SIGMAR1HTR1A | |
| SCHEMBL31258111 | 0.73 | MTNR1A (0.56) | TP53 | |
| SCHEMBL31258122 | 0.73 | MTNR1A (0.56) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365545-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2021257092-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| CN-108430972-A | α, β unsaturated acyl amine compounds | 协和发酵麒麟株式会社 | 2018-08-21 | — | — | CN | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2324032-B1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8143304-B2 | (3-amino-1,2,3,4-tetrahydro-9 H-carbazol-9-yl)-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2051962-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-04-29 | — | — | EP | disclosed |
| CN-101255221-A | Olefin-diene copolymer and process for producing the same | SUMITOMO CHEMICAL CO (JP) | 2008-09-03 | — | — | CN | disclosed |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
| WO-2008017989-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-14 | — | — | WO | disclosed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| CN-1860112-A | 3-amino chroman and 2-amino tetralin derivatives | WYETH CORP (US) | 2006-11-08 | — | — | CN | disclosed |
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | RENOVIS, INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012291-A1 | 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | PARK7, UACA, PTGER4 | NISCH 1871/4885TP53 4516/4885SIGMAR1 1886/4885 |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | NISCH 1432/4885TP53 1465/4885SIGMAR1 1663/4885 |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | NISCH 2683/4885TP53 4589/4885SIGMAR1 681/4885 |
| US-20230365545-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ALDH1A2, NR2E3, RB1 | NISCH 3309/4885TP53 3162/4885SIGMAR1 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.